Development
AbCellera Biologics Inc.
ABCL
$4.59
$0.092.00%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -192.35% | -152.00% | -136.89% | -124.49% | 3.29% |
| Total Depreciation and Amortization | 25.07% | 27.16% | 39.74% | 47.06% | 43.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -9.19% | 26.32% | 60.82% | 69.45% | 99.75% |
| Change in Net Operating Assets | -55.66% | 143.57% | -261.03% | 455.62% | -28.43% |
| Cash from Operations | -115.82% | -97.11% | -134.24% | -43.43% | 13.40% |
| Capital Expenditure | -8.90% | -10.46% | -5.02% | -2.66% | -20.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.87% | 48.32% | -67.04% | -54.46% | -7.48% |
| Cash from Investing | 37.30% | 36.49% | -48.93% | -38.83% | -6.13% |
| Total Debt Issued | 320.69% | 740.66% | -44.00% | -26.24% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 71.85% | 76.07% | 77.57% | 97.43% | 12.34% |
| Cash from Financing | 736.12% | 4,953.15% | -62.40% | 119.09% | 58.11% |
| Foreign Exchange rate Adjustments | 106.14% | 98.90% | -253.18% | -739.13% | -573.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.72% | -70.38% | -2,554.57% | -207.82% | 6.97% |